Structure Therapeutics Inc. 8-K Filing

Ticker: GPCR · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1888886

Structure Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyStructure Therapeutics Inc. (GPCR)
Form Type8-K
Filed DateDec 8, 2025
Pages9
Reading Time11 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Structure Therapeutics Inc. (ticker: GPCR) to the SEC on Dec 8, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.0001 (ting three ordinary shares, par value $0.0001 per ordinary share GPCR Nasdaq Glo).

How long is this filing?

Structure Therapeutics Inc.'s 8-K filing is 9 pages with approximately 2,741 words. Estimated reading time is 11 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 2,741 words · 11 min read · ~9 pages · Grade level 12.9 · Accepted 2025-12-08 08:47:01

Key Financial Figures

  • $0.0001 — ting three ordinary shares, par value $0.0001 per ordinary share GPCR Nasdaq Glo

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 8, 2025, Structure Therapeutics Inc. (the Company) issued a press release announcing data from its ACCESS clinical program of aleniglipron, the company's once-daily oral small molecule glucagon-like-peptide-1 (GLP-1) receptor agonist (GLP1-RA) for the treatment of obesity. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On December 8, 2025, the Company made available on its website an investor presentation to be shared with investors and others from time to time. A copy of this presentation is being furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information set forth in this Item 7.01 and in the press release and investor presentation attached hereto as Exhibits 99.1 and 99.2, respectively, is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section. The information set forth in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent that the Company specifically incorporates it by reference.

01 Other Events

Item 8.01 Other Events. Summary of Data from the ACCESS Clinical Program The Company's ACCESS clinical program includes 36-week data from the core Phase 2b ACCESS study and exploratory ACCESS II study, and interim data from Phase 2 body composition study and Phase 2b ACCESS open label extension (OLE) study, as follows: The Phase 2b ACCESS study demonstrated a placebo-adjusted mean weight loss of 11.3% with 120 mg dose at 36 weeks. The exploratory ACCESS II dose exploration study demonstrated a placebo-adjusted mean weight loss of 15.3% at 240 mg at 36 weeks. No adverse event-related treatment discontinuations were observed when starting at the lower 2.5 mg dose in ACCESS Open Label Extension and Body Composition Study The Company believes that the data from the ACCESS clinical program supports and informs the advancement to Phase 3 clinical development program in mid-2026. The description of each study and the data observed is set forth below. Phase 2b ACCESS study - Evaluating target doses of up to 120 mg The core 36-week Phase 2b ACCESS study was a randomized, double-blind, placebo-controlled, Phase 2b dose-range finding clinical study that enrolled 230 adult participants living with obesity (body mass index (BMI) 30 kg/m2), or overweight (BMI 27 kg/m2) with at least one weight-related comorbidity. Participants were enrolled in 36 participating sites across the United States. Participant ages ranged from 49 to 52 years and participants were predominantly female (53% to 55%) with a baseline BMI of 39. HbA1c and blood pressure, according to the eligibility criteria, were within normal limits. All participants were randomized 3:1 (active:placebo) and started at 5 mg of aleniglipron (or placebo) with a 4-week titration schedule, reaching target doses of 45 mg, 90 mg or 120 mg once-daily. Each of the three doses in the ACCESS study achieved statistical significance on the primary endpoint and all key secondary endpoints. Primary efficacy estimand 1 re

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company's future plans and prospects; any expectations regarding the potential benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects and future application of aleniglipron; the belief that data to date from the Phase 2b ACCESS, exploratory ACCESS II, body composition, and the Phase 2b ACCESS OLE studies support and inform advancement of the Phase 3 clinical development of aleniglipron; the expected timing for the meeting with the FDA to finalize the Phase 3 trial design and the Phase 3 program initiation of aleniglipron; the expected timing of topline data readouts from the exploratory ACCESS II, body composition, the Phase 2b ACCESS OLE, SWITCH and T2DM studies; the planned initiation of the ACCG-3535 Phase 1 study and the timing thereof; the expected timing of study results from the Phase 1 ACCG-2671 study; and any presumption that topline, interim or preliminary data will be representative of final data or data in later clinical trials. In addition, when or if used in this Current Report on Form 8-K, the words and phrases "anticipate," "believe," "expect," "may," "plan," "potential," "to be," "will," and similar expressions and their variants, as they relate to the Company may identify forward-looking the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers ar

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated December 8, 2025. 99.2 Investor Presentation, dated December 8, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Structure Therapeutics Inc. Date: December 8, 2025 By: /s/ Raymond Stevens Raymond Stevens, Ph.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.